Perspectives
"Investment in biologics based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment options, higher returns on investment and slower erosion of market share post patent expiry compared to small molecule based drugs.
See our 20 pg report, "Ever Greening” To Remain Evergreen: Evolution of Antibody Technology to Drive M&A", for further details.
" ... Read more
6 Jan 2010 | From the latest Perspectives entry by Subita Srimal, Developing “Better Biologics” through "Evergreening "= High Value Proposition
Research Library . Recent Updates
| 30 Jun 2010 | AZN, Underperform - AZN-1Q Results – Topline sustainability remains unaddressed » |
|---|---|
| 30 Jun 2010 | ASTRAZENECA, Underperform - Favorable Crestor Ruling – Does not solve the fundamental issues » |
| 25 Jun 2010 | NOVOB & SAN-Market Perf, Insulin Degludec at ADA - PhII clinical results does not match the optimism » |
| 25 Jun 2010 | SGLT2 Inhibitors at ADA 10 » |
| 24 Jun 2010 | SUNP - Outperform, WPL +ve Investment Alert - Para IV Settlements For Sun And WPL » |
| 23 Jun 2010 | Intermune, Outperform - No Near Term Catalysts - EU Approval: A Wild Card » |
